Anti‐human‐cytomegalovirus immunoglobulin G levels in glioma risk and prognosis

Abstract

The role of human cytomegalovirus ( HCMV ) in glioma development and progression remains controversial. The purpose of our study was to assess the potential associations between anti‐ HCMV antibodies (immunoglobulin G [ IgG ] and immunoglobulin M [ IgM ]) and glioma risk and prognosis using data from the H arris C ounty C ase– C ontrol S tudy. Multivariable logistic regression models were utilized to estimate odds ratios and 95% confidence intervals ( CI ) for the associations between glioma status and antibody levels among glioma cases ( n  = 362) and cancer‐free controls ( n  = 462). Hazard ratios and 95% CI s were calculated using C ox proportional hazards regression, adjusting for age, race, and sex, to determine if antibody levels were associated with survival over time among cases. Among IgG ‐positive participants, increasing anti‐ HCMV IgG levels were associated with decreasing glioma risk ( P for trend = 0.0008), and those with the lowest level of anti‐ HCMV IgG (<10 U/mL) had the highest glioma risk, controlling for age, sex, and race/ethnicity ( OR : 2.51, 95% CI : 1.42–4.43). Antibody levels were not associated with survival among glioma cases. Our study contributes new evidence toward the potential importance of the direct and indirect effects of HCMV infection in gliomagenesis.